Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.

Feng-Cai ZhuWei Chen


This is the first randomised controlled trial for assessment of the immunogenicity and safety of a candidate non-replicating adenovirus type-5 (Ad5)-vectored COVID-19 vaccine, aiming to determine an appropriate dose of the candidate vaccine for an efficacy study. This randomised, double-blind, placebo-controlled, phase 2 trial of the Ad5-vectored COVID-19 vaccine was done in a single centre in Wuhan, China. Healthy adults aged 18 years or older, who were HIV-negative and previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection-free, were eligible to participate and were randomly assigned to receive the vaccine at a dose of 1 × 1011 viral particles per mL or 5 × 1010 viral particles per mL, or placebo. Investigators allocated participants at a ratio of 2:1:1 to receive a single injection intramuscularly in the arm. The randomisation list (block size 4) was generated by an independent statistician. Participants, investigators, and staff undertaking laboratory analyses were masked to group allocation. The primary endpoints for immunogenicity were the geometric mean titres (GMTs) of specific ELISA antibody responses to the receptor binding domain (RBD) and neutralising antibody responses at day 28. The primar...Continue Reading


Jul 31, 2020·Oral Diseases·Gulshan Sunavala-Dossabhoy, Andrew I Spielman
Sep 10, 2020·British Journal of Nursing : BJN·Jacqueline Boulton
Aug 18, 2020·Transboundary and Emerging Diseases·Guangzhi ZhangShangjin Cui
Sep 8, 2020·Environmental Microbiology·Harald Brüssow
Sep 25, 2020·Current Opinion in HIV and AIDS·Xin LiJasper Fuk-Woo Chan
Oct 1, 2020·Human Vaccines & Immunotherapeutics
Oct 1, 2020·Journal of Gastrointestinal Cancer·Mohammad Hossein AntikchiMohammad Hossein Jarahzadeh
Sep 24, 2020·Nature·Florian Krammer
Aug 8, 2020·Nature Biomedical Engineering
Aug 28, 2020·Vaccines·Mohammed A Rohaim, Muhammad Munir
Aug 14, 2020·Pharmaceuticals·Shipra MalikRaman Bahal
Aug 26, 2020·BMJ : British Medical Journal·Sarah Caddy
Sep 6, 2020·Nature Reviews. Immunology·Mangalakumari JeyanathanZhou Xing
Sep 10, 2020·Experimental Hematology & Oncology·Ehtisham Ul HaqJiancheng Guo
Aug 2, 2020·BMJ : British Medical Journal·Herb F SewellDenise Kendrick
Aug 8, 2020·BMJ : British Medical Journal·Elisabeth Mahase
Sep 6, 2020·Military Medical Research·Ying-Hui JinUNKNOWN Chinese Research Hospital Association (CRHA)
Sep 6, 2020·International Journal of Molecular Sciences·Wenli ZhangAnja Ehrhardt
Sep 30, 2020·Nature Biotechnology·Laura DeFrancesco
Sep 26, 2020·Frontiers in Pharmacology·Rudra P SahaChiranjib Chakraborty
Sep 28, 2020·Protein Science : a Publication of the Protein Society·Dariusz BrzezinskiWladek Minor
Oct 13, 2020·Nucleic Acids Research·Shuyi FangJun Wan
Oct 8, 2020·Nature Reviews. Microbiology·Ben HuZheng-Li Shi
Oct 13, 2020·Frontiers in Microbiology·Yuki Furuse, Hitoshi Oshitani
Sep 17, 2020·Clinical and Experimental Immunology·John S TregoningKatrina M Pollock
Oct 15, 2020·Signal Transduction and Targeted Therapy·Yetian DongFangfang Zhou
Oct 25, 2020·Nature Medicine·UNKNOWN IHME COVID-19 Forecasting Team
Nov 4, 2020·Future Microbiology·Kenneth Lundstrom
Nov 4, 2020·Human Vaccines & Immunotherapeutics·Fiona M Russell, Brian Greenwood
Nov 6, 2020·Médecine sciences : M/S·Emmanuelle Billon-Denis, Jean-Nicolas Tournier
Oct 29, 2020·Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology·Christiane Sigrid Eberhardt, Claire-Anne Siegrist
Oct 29, 2020·Scandinavian Journal of Immunology·Xiao-Hua LuoRui-Chan Du
Sep 11, 2020·Disaster Medicine and Public Health Preparedness·Rima MoghniehAbdul Rahman Bizri
Dec 4, 2020·Human Vaccines & Immunotherapeutics·Vipin M Vashishtha, Puneet Kumar
Oct 22, 2020·Viruses·Laura Fernandez-GarciaMaria Tomás
Dec 16, 2020·SLAS Discovery·Dawid MaciorowskiAdinarayana Kunamneni
Nov 6, 2020·Transplantation·Yorg AzziEnver Akalin

❮ Previous
Next ❯

Datasets Mentioned


Methods Mentioned


Clinical Trials Mentioned


Software Mentioned


Related Concepts

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.


Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.


Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.